Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($0.92), $0.20 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $11.45 million versus the consensus estimate of $12.14 million.

Financial Guidance: For the year ending December 31, 2023, Rhythm continues to anticipate approximately $200 million to $220 million in Non-GAAP Operating Expenses (see below under "Non-GAAP Financial Measures" for more details), comprised of $120 million to $130 million from R&D expenses and $80 million to $90 million from S,G&A expenses. Based on its current operating plans, Rhythm expects that its existing cash, cash equivalents and short-term investments as of March 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.